Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 04, 2021

Eltrombopag for Managing Thrombocytopenia Associated With TKI Therapy in Patients With CML and Myelofibrosis

Haematologica

 

Additional Info

Haematologica
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis
Haematologica 2021 Nov 01;106(11)2853-2858, M Shoukier, G Borthakur, E Jabbour, F Ravandi, G Garcia-Manero, T Kadia, J Matthews, L Masarova, K Naqvi, K Sasaki, S Verstovsek, J Cortes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading